Skip to main content
. 2012 Apr 17;120(3):560–568. doi: 10.1182/blood-2011-12-397893

Figure 3.

Figure 3

Case study before and after brentuximab vedotin therapy. Positron emission tomography scans before (A) and after (B) 9 cycles of brentuximab vedotin for a 20-year-old patient who had been diagnosed with HL 3 years earlier. The patient had received 4 cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide followed by external beam radiation that yielded a CR lasting 2 months. She was next treated with 2 cycles of ICE, achieving a PR lasting 1 month. Subsequently, gemcitabine, vinorelbine, and doxorubicin (GND), followed by BEAM autoSCT yielded a PR lasting 3 months. She underwent alloSCT for relapsed disease, conditioned with busulfan, fludarabine, and total body irradiation (200 cGy) and had a matched, unrelated donor, but experienced disease progression 4 months after alloSCT. She received her first dose of brentuximab vedotin in December 2009, achieved a PR before the third dose, and a CR was reported after the ninth dose. She completed 16 treatment cycles and remained in CR at the last contact, 6 months after the last dose of brentuximab vedotin.